Salze und Salzhydrate von N,n'-BIS[2-(1H-Imidazol-4-Yl)ethyl!oxalamid zur Behandlung von Husten und Fibrose der Lunge, Nieren, Pankreas und Herz

Details

Veröffentlichungs-Nr.

EP4818160

Anmeldetag

2. April 2025

Veröffentlichung

7. Oktober 2026

Rechtsraum

EP

Abstract

The invention relates to the chemistry of organic compounds, pharmacology, and medicine, and concerns the prevention and treatment of fibrosis of the liver, kidneys, pancreas, heart (myocardial fibrosis), and lungs, preferably of idiopathic origin, as well as to cough, particularly subchronic and chronic cough, and more specifically, cough associated with idiopathic pulmonary fibrosis (IPF), by means of salt forms of N,N'-bis[2-(1H-imidazol-4-yl)ethyl]oxalamide of formula (I) <img class="EMIRef" id="5cb757ce-a80f-4088-b745-16200b5f6bc9-ia01" /> wherein A presents HCl, H<3>PO<4>, maleic acid, malonic acid, fumaric acid, HI, HBr, H<2>SO<4>, benzenesulfonic acid, tartaric acid, malic acid, p-toluenesulfonic acid, oxalic acid, glycolic acid, glutaric acid, camphorsulfonic acid, methanesulfonic acid, formic acid, ethanesulfonic acid, mandelic acid, nicotinic acid, succinic acid, and adipic acid; n represents 1 or 2, and z represents an integer from 0 to 3. The present invention also relates to methods for preparing compounds of formula (I), pharmaceutical compositions comprising a therapeutically effective amount of the salt according to the invention, and methods of treatment.

Anmelder

Firma

Treamid Therapeutics GmbH

Land

🇩🇪 Deutschland